1. Home
  2. MCHX vs BEAT Comparison

MCHX vs BEAT Comparison

Compare MCHX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

N/A

Current Price

$1.63

Market Cap

70.3M

ML Signal

N/A

BEAT

Heartbeam Inc.

HOLD

Current Price

$2.27

Market Cap

63.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCHX
BEAT
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Retail: Computer Software & Peripheral Equipment
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
70.3M
63.5M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
MCHX
BEAT
Price
$1.63
$2.27
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.75
AVG Volume (30 Days)
33.8K
30.8M
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$46,494,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$0.54
52 Week High
$2.40
$3.48

Technical Indicators

Market Signals
Indicator
MCHX
BEAT
Relative Strength Index (RSI) 48.29 74.82
Support Level $1.60 $0.66
Resistance Level $1.70 $2.82
Average True Range (ATR) 0.08 0.26
MACD 0.01 0.18
Stochastic Oscillator 66.67 75.67

Price Performance

Historical Comparison
MCHX
BEAT

About MCHX Marchex Inc. Class B

Marchex Inc harnesses the power of AI and conversational intelligence to provide actionable insights aligned with prescriptive vertical market data analytics, driving operational excellence and revenue acceleration. Marchex enables executive, sales, and marketing teams to optimize customer journey experiences across communications channels, enabling enterprise strategies, empowering businesses to increase revenue through informed decision-making and strategic execution.

About BEAT Heartbeam Inc.

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: